(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 67.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Ocular Therapeutix's revenue in 2026 is $52,054,000.On average, 14 Wall Street analysts forecast OCUL's revenue for 2026 to be $11,838,832,596, with the lowest OCUL revenue forecast at $10,933,356,373, and the highest OCUL revenue forecast at $12,961,948,145. On average, 14 Wall Street analysts forecast OCUL's revenue for 2027 to be $22,536,980,374, with the lowest OCUL revenue forecast at $12,482,965,937, and the highest OCUL revenue forecast at $42,199,189,036.
In 2028, OCUL is forecast to generate $60,381,186,748 in revenue, with the lowest revenue forecast at $22,984,996,745 and the highest revenue forecast at $98,939,144,693.